A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts ...

The candidate plans to enter Phase I human trials in early 2026. GATC’s MAT platform not only identifies potential new drugs but also provides comprehensive analytic reports assessing their likelihood ...

The forward-looking statements include statements regarding maximizing efficiency, cost-effectiveness, and the likelihood of success of Adial’s upcoming trial, enabling a refined Phase 3 ...

Early adopters have already cited significant benefits, including accelerated timelines, lower upfront costs, and reduced manufacturing complexity for their phase-appropriate needs.

The drug Leqembi (lecanemab-irmb), which began development in 2005 as a collaboration by Eisai (ESAI.Y 0.3%), Biogen (BIIB 1.96%), and BioArctic (BRCT.F -1.29%), received approval from the FDA in ...

Edesa Biotech reports financial updates, equity financing for vitiligo drug, and plans for Phase 2 study in 2025. Quiver AI Summary Edesa Biotech, Inc. has announced its financial results for the ...

The company announced it has "dosed" the first patients in Phase I trials, meaning, administering doses of its drug, ABS-101, to healthy volunteers. "This is a very big milestone for the company ...

With a Growing List of 30+ Global Customers, Including Top Pharma, PhaseV is Poised to Transform Clinical Development at Scale with its Vertical AI Platform BOSTON, May 13, 2025 /PRNewswire/ -- PhaseV ...

The cost to develop drugs is about $2.6 billion per drug. New drugs can take 10-15 years to develop, and more than 90% fail in clinical trials mainly because they’re deemed unsafe for humans.

FDA plans to phase out animal testing in drugs in what it calls a ‘paradigm shift’ ‘Thousands of animals could eventually be spared each year as these new methods take root,’ said ...

April 10 (Reuters) - The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human ...

On February 7, Conduit Pharmaceuticals announced that it completed Phase I of its collaboration with Sarborg Limited and is now moving to Phase II, focusing on AI and cybernetics in drug development.